United States Patent 9,259,425: Claim Scope, Patent Expiration, Orange Book Status, and Generic Entry Risk

U.S. Patent No. 9,259,425 protects methods of whitening the eye and reducing ocular redness with low-concentration selective alpha-2 adrenergic receptor agonists. Its commercially important embodiment is brimonidine ophthalmic solution at 0.01% to 0.025% weight by volume, including the 0.025% concentration used in Lumify. The patent is method-of-use protection, not a broad composition patent. Its principal enforcement risk concerns labeled or induced use of low-dose brimonidine for cosmetic ocular redness.

The patent was granted on February 16, 2016. Public patent records identify an expiration date of approximately April 8, 2029, subject to any applicable patent-term adjustment or disclaimer. The central commercial exposure is the 0.025% brimonidine redness-relief product marketed by Bausch + Lomb.

What does U.S. Patent 9,259,425 protect?

The patent protects administering a composition containing a selective alpha-2 adrenergic receptor agonist to increase eye whiteness, reduce eye redness, or achieve both results.

The claims cover two levels of subject matter:

Claim group	Protected activity	Active ingredient scope	Concentration
Claims 1-2	Increasing eye whiteness	Listed selective alpha-2 agonists; claim 2 narrows to brimonidine	Claim 1: about 0.001%-0.05%; claim 2: about 0.01%-0.025%
Claims 3-4	Reducing eye redness	Listed selective alpha-2 agonists; claim 4 narrows to brimonidine	Claim 3: about 0.001%-0.05%; claim 4: about 0.01%-0.025%
Claims 5-6	Simultaneously reducing redness and increasing whiteness	Listed selective alpha-2 agonists; claim 6 narrows to brimonidine	Claim 5: about 0.001%-0.05%; claim 6: about 0.01%-0.025%

The listed compounds are lofexidine, apraclonidine, mivazerol, clonidine, brimonidine, alpha-methyl dopa, guanfacine, dexmedetomidine, and two additional alpha-2 agonists identified by chemical name.

The practical claim center is claims 2, 4, and 6. Those claims require brimonidine at a concentration from about 0.01% to about 0.025%, which captures a 0.025% product directly.

How broad are the independent claims?

Claims 1, 3, and 5 are broad because they cover an entire listed class of active ingredients rather than brimonidine alone.

Claim 1: increasing whiteness

Claim 1 requires:

A subject in need of treatment.
Administration of a composition.
A listed selective alpha-2 adrenergic receptor agonist or pharmaceutically acceptable salt.
A concentration of approximately 0.001% to 0.05% weight by volume.
A method that increases eye whiteness.

The claim does not require a particular dosage form in its text. It does not expressly require an aqueous solution, preservative, pH range, dosing frequency, bottle design, or specific excipient. A product can potentially fall within the claim if it uses an alternative ophthalmic formulation, provided the active ingredient and concentration limitations are met and the claimed result is achieved.

Claim 3: reducing redness

Claim 3 has substantially the same structural limitations as claim 1 but focuses on reducing redness. This is the most commercially relevant functional limitation because products such as Lumify are labeled for relief of ocular redness.

Claim 5: dual effect

Claim 5 requires both outcomes: reduction of redness and simultaneous increase in whiteness. A product used and labeled for redness relief may also implicate claim 5 if the evidence establishes the whitening effect. The dual-result limitation may create a narrower infringement proof issue than claim 3 because the patentee must establish both claimed effects.

What does the brimonidine concentration range cover?

The dependent brimonidine claims cover concentrations from approximately 0.01% through approximately 0.025% weight by volume.

Product concentration	Likely relationship to claims 2, 4, and 6
0.001%	Outside the specific brimonidine dependent range but potentially within claims 1, 3, and 5
0.005%	Outside claims 2, 4, and 6 but potentially within the independent claims
0.01%	Within the lower boundary of the dependent range
0.015%	Within the dependent range
0.02%	Within the dependent range
0.025%	Within the upper boundary and the principal commercial embodiment
0.05%	Within the independent claims but outside the narrower brimonidine dependent range if the endpoint is construed strictly

The words “about” introduce numerical interpretation issues. Courts generally assess the ordinary meaning of the term in the technical and patent context, including formulation tolerances, measurement precision, and prosecution history. A product slightly above or below a stated concentration may still present literal infringement risk, although the precise result depends on claim construction and the evidence of what the patent teaches.

What formulations are protected by U.S. Patent 9,259,425?

The patent claims methods using a composition. They do not, in the provided claims, require a particular formulation architecture.

Potentially covered formulations include:

Preserved or preservative-free ophthalmic solutions.
Multidose or unit-dose products.
Aqueous brimonidine solutions.
Formulations containing brimonidine tartrate.
Formulations with buffering agents, tonicity agents, viscosity modifiers, or solubilizers.
Formulations administered as drops or through another ocular delivery device.

The claims do not expressly protect:

A specific bottle or dispensing mechanism.
A particular preservative system.
A defined pH range.
A specific osmolality.
A particular particle size or polymorph.
A manufacturing process.
A composition claim covering brimonidine itself.

That distinction matters. A competitor may avoid formulation-specific patent claims by changing excipients or packaging, but it may still infringe the method claims if its product contains brimonidine within the claimed concentration and is directed to ocular redness or whitening.

What is the Orange Book status of the patent?

Lumify is an FDA-approved over-the-counter ophthalmic product containing brimonidine tartrate 0.025%. The active ingredient is not new to FDA regulation. Brimonidine was previously approved at higher concentrations for glaucoma and ocular hypertension.

The commercial and regulatory structure is therefore different from a new chemical entity:

Issue	Assessment
Drug	Brimonidine tartrate ophthalmic solution, 0.025%
Commercial product	Lumify
Sponsor	Bausch + Lomb
FDA pathway	NDA-based approval for low-dose redness relief
New chemical entity exclusivity	Not expected because brimonidine was previously approved
Three-year exclusivity	Potentially applicable to qualifying new clinical investigations, but the original period would have expired
Patent type	Method-of-use patent
Principal patent date	Grant: February 16, 2016
Projected patent expiration	Approximately April 8, 2029
Biosimilar pathway	Not applicable

Orange Book listing status must be evaluated against the applicable FDA edition and any later delisting or listing changes. The patent’s commercial relevance is strongest if it remains listed for the reference product and is tied to the approved redness-relief indication. Under the Hatch-Waxman framework, an ANDA applicant may need to address listed patents through a Paragraph IV certification or pursue a later approval date based on the patent listing and exclusivity record. [FDA, 2024a; 21 U.S.C. § 355]

When does brimonidine redness-relief exclusivity end?

The relevant patent protection is projected to end around April 8, 2029. Regulatory exclusivity, if any, is separate and would have ended earlier because the product was approved in 2017 and brimonidine was already an approved active ingredient.

The practical exclusivity timeline is:

Date or period	Event
April 8, 2009	Earliest priority date associated with the patent family, based on public patent records
February 16, 2016	U.S. Patent 9,259,425 granted
December 2017	FDA approval of Lumify for ocular redness
Approximately 2020	Any ordinary three-year clinical-investigation exclusivity would have expired
April 8, 2029	Projected patent expiration
After expiration	ANDA-based generic entry becomes materially less constrained by this patent, subject to other listed patents and litigation

A patent expiration date does not itself authorize immediate generic launch. An ANDA applicant must still obtain FDA approval, satisfy patent-certification requirements, and resolve any litigation-based 30-month stay or settlement restrictions. [FDA, 2024b]

Are Paragraph IV challenges likely?

A Paragraph IV challenge would be the standard route for an ANDA applicant seeking approval before expiration of a listed patent. The applicant would certify that the patent is invalid, unenforceable, or not infringed.

The strongest potential Paragraph IV arguments would likely concern:

Claim construction

An ANDA applicant could argue that its product does not satisfy “about 0.025%,” the claimed treatment result, or the requirement that the subject be “in need thereof.” The strength of those arguments would depend on the product label, formulation specification, and patent prosecution history.

Obviousness

The patent combines:

A known pharmacologic class.
A known ocular agent, brimonidine.
A low concentration.
A cosmetic or redness-relief indication.

An obviousness challenge would likely rely on earlier brimonidine glaucoma literature, alpha-2 agonist pharmacology, ocular vasoconstriction data, and prior art concerning ocular redness. The patentee would counter that the claimed low-dose use produced a clinically useful whitening effect without the adverse effects associated with traditional ocular vasoconstrictors.

Written description and enablement

The independent claims cover a broad list of alpha-2 agonists and a broad concentration range. An accused party could argue that the disclosure does not adequately support the full genus or all claimed concentrations. The patentee would argue that the common pharmacologic mechanism and disclosed examples support the claimed class.

Infringement

A generic applicant could attempt to avoid induced infringement by using a label that omits redness relief or whitening. That strategy is difficult if FDA approval requires or preserves the same indication as the reference product. The commercial value of a low-dose brimonidine product is closely tied to its redness-relief labeling.

Which companies may challenge the patent?

The principal potential challengers are generic ophthalmic manufacturers with the capacity to develop sterile brimonidine solutions. Relevant competitive categories include:

Large generic companies filing ANDAs.
Ophthalmic specialists with sterile manufacturing capacity.
Contract manufacturers supplying private-label redness-relief products.
Companies pursuing alternative alpha-2 agonist products.
Retailers or consumer-health companies seeking store-brand equivalents.

A definitive list of named challengers requires current FDA ANDA records, Orange Book certifications, and federal court docket review. The patent itself does not identify future challengers, and the supplied claim text does not establish that any particular company has filed a Paragraph IV certification.

What patent litigation affects Lumify and brimonidine 0.025%?

The key litigation risk is an ANDA action under 35 U.S.C. § 271(e)(2), in which filing an ANDA with a Paragraph IV certification can constitute an artificial act of infringement before commercial launch.

Potential litigation issues include:

Issue	Business consequence
Validity	Determines whether the 2029 date has practical value
Claim construction	Determines whether low-dose brimonidine and the proposed label fall within the claims
Induced infringement	Determines whether a generic label creates liability
30-month stay	Can delay FDA approval after timely patent litigation
Settlement	May establish a negotiated launch date before patent expiration
Covenants or licenses	May permit entry under defined commercial conditions
Additional patents	Can preserve exclusivity after one patent is invalidated or expires

No settlement terms should be inferred from the existence of this patent alone. A settlement may include a licensed entry date, supply arrangement, manufacturing restriction, or no-admission clause. Those terms are often confidential or recorded only in litigation filings and FTC settlement materials.

How strong is the patent estate?

U.S. Patent 9,259,425 has meaningful commercial strength against the principal 0.025% brimonidine product because its dependent claims expressly identify brimonidine and the concentration range used by the reference product.

Its strengths are:

Direct coverage of the marketed concentration.
Coverage of the principal therapeutic and cosmetic result.
Separate claims for redness reduction, whitening, and both outcomes.
Method-of-use protection that can align with an FDA-approved label.
Coverage extending beyond brimonidine in the independent claims.

Its limitations are:

The claims are not composition claims.
They do not expressly cover manufacturing methods or delivery devices.
The independent claims may face prior-art and obviousness scrutiny.
A generic may attempt a label carve-out.
A competing formulation can remain commercially relevant if it uses a different active ingredient or concentration.
Patent expiration occurs well before the end of a long-term commercial lifecycle for the product.

The patent is stronger against a directly substituted 0.025% brimonidine product than against an alternative alpha-2 agonist, a materially different concentration, or a product with a non-redness label.

How does Lumify compare with other ocular redness products?

Lumify differs from traditional redness-relief products because it uses brimonidine, a selective alpha-2 adrenergic agonist, rather than classic alpha-1 or mixed adrenergic vasoconstrictors such as tetrahydrozoline or naphazoline.

Product category	Typical active class	Main patent issue
Low-dose brimonidine	Selective alpha-2 agonist	U.S. Patent 9,259,425 and related product patents
Tetrahydrozoline products	Imidazoline or adrenergic vasoconstrictor	Older composition, formulation, and branding rights
Naphazoline products	Imidazoline vasoconstrictor	Generally mature generic competition
Apraclonidine products	Alpha-2 agonist with alpha activity	Different safety, labeling, and formulation profile
Preservative-free alternatives	Varies	Delivery-system and formulation patents may dominate

The most direct competitive threat is a generic brimonidine 0.025% product. Alternative active ingredients are less likely to infringe the brimonidine dependent claims but may still raise issues under the broader independent claims if the active ingredient, concentration, and claimed ocular effect are covered.

Does biosimilar risk apply?

No. Biosimilar law does not apply because brimonidine is a chemically synthesized small molecule, not a biologic subject to the Biologics Price Competition and Innovation Act.

The relevant pathway is an ANDA under section 505(j) of the Federal Food, Drug, and Cosmetic Act. A follow-on manufacturer would generally need to demonstrate pharmaceutical equivalence and bioequivalence, while addressing listed patents through the applicable certification process. [FDA, 2024b]

What manufacturing and geographic barriers remain?

The patent is a U.S. right. It does not block manufacture or sale outside the United States unless corresponding foreign patents exist.

A generic entrant still faces technical barriers:

Sterile ophthalmic manufacturing.
Consistent low-level brimonidine assay control.
Container-closure compatibility.
Microbial control and preservative performance.
Stability over the proposed shelf life.
FDA inspection and quality-system requirements.
Commercial-scale filling and packaging.

The patent does not itself create a manufacturing monopoly. A competitor could potentially use a different process or facility, but the finished product and label could still fall within the asserted method claims.

What revenue exposure does the patent create?

The patent protects the commercial period during which Lumify benefits from limited direct substitution. Revenue exposure is concentrated in the consumer ophthalmic redness-relief segment rather than the glaucoma market, where brimonidine has long faced generic competition.

The main scenarios are:

Scenario	Commercial effect
Patent upheld and no early settlement	Branded product retains stronger protection until approximately 2029
Patent invalidated	Generic entry could occur after FDA approval and resolution of other barriers
Narrow label carve-out	Generic may enter with restricted indications, limiting direct substitution
Settlement with licensed entry	Competition begins on the agreed date
Patent expiration without competing patents	Broadest opportunity for generic launch
Alternative alpha-2 product	Competitive pressure without direct brimonidine substitution

Key Takeaways

U.S. Patent 9,259,425 is a method-of-use patent covering low-dose alpha-2 agonists for ocular whitening and redness reduction.
Claims 2, 4, and 6 directly target brimonidine concentrations from about 0.01% to about 0.025%.
The patent’s principal commercial relevance is Lumify, a 0.025% brimonidine tartrate ophthalmic product.
The projected patent expiration is approximately April 8, 2029.
Regulatory exclusivity would have expired substantially earlier than the patent term.
The patent does not claim a specific formulation, bottle, excipient system, or manufacturing process.
A Paragraph IV challenge would likely focus on obviousness, claim construction, written description, enablement, and label-based infringement.
Biosimilar competition is irrelevant; ANDA-based generic competition is the applicable pathway.
The patent is strongest against a directly substituted brimonidine 0.025% product with a redness-relief label.
Additional listed patents, continuations, settlements, or confidential licenses could alter the practical launch date.

FAQs

What concentration of brimonidine is most clearly covered by U.S. Patent 9,259,425?

Brimonidine at 0.025% is the clearest commercial embodiment because claims 2, 4, and 6 expressly cover brimonidine from about 0.01% to about 0.025% weight by volume.

Can a generic avoid the patent by using brimonidine at 0.005%?

A 0.005% product would fall outside the narrower dependent claims if the concentration is construed strictly, but it could still implicate the broader independent claims covering approximately 0.001% to 0.05%.

Is U.S. Patent 9,259,425 a formulation patent?

No. The supplied claims are method claims. They require administration of a composition containing the specified active ingredient and concentration, but they do not require a particular excipient or packaging system.

Can an alternative alpha-2 agonist compete with Lumify without infringing?

Not necessarily. The independent claims cover several alpha-2 agonists besides brimonidine. A competing product would need to assess the active ingredient, concentration, indication, and evidence of the claimed whitening or redness-reduction result.

What is the primary generic-launch risk after April 2029?

The principal risk is FDA-approved ANDA entry for brimonidine 0.025% with a label directed to ocular redness. Other patents, regulatory requirements, litigation settlements, and manufacturing readiness could still affect the actual launch date.

References

U.S. Patent No. 9,259,425. (2016). Methods of increasing eye whiteness. United States Patent and Trademark Office.
U.S. Food and Drug Administration. (2024a). Approved drug products with therapeutic equivalence evaluations. Orange Book.
U.S. Food and Drug Administration. (2024b). ANDA submissions: Refuse-to-receive standards. Center for Drug Evaluation and Research.
Federal Food, Drug, and Cosmetic Act, 21 U.S.C. § 355.
Patent Act, 35 U.S.C. §§ 271(e)(2), 281, 282.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Bausch And Lomb Inc	LUMIFY	brimonidine tartrate	SOLUTION/DROPS;OPHTHALMIC	208144-001	Dec 22, 2017		OTC	Yes	Yes	9,259,425	⤷ Start Trial				RELIEVES REDNESS OF THE EYE DUE TO MINOR EYE IRRITATIONS	⤷ Start Trial
Bausch And Lomb Inc	LUMIFY PRESERVATIVE FREE	brimonidine tartrate	SOLUTION/DROPS;OPHTHALMIC	218424-001	Apr 19, 2024		OTC	Yes	Yes	9,259,425	⤷ Start Trial				RELIEVES REDNESS OF THE EYE DUE TO MINOR EYE IRRITATIONS	⤷ Start Trial
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Patented / Exclusive Use	>Submissiondate

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Brazil	112016004054	⤷ Start Trial
Canada	2732521	⤷ Start Trial
Canada	2782817	⤷ Start Trial
Canada	2832953	⤷ Start Trial
Canada	2865593	⤷ Start Trial
Cyprus	1115727	⤷ Start Trial
Denmark	2320911	⤷ Start Trial
>Country	>Patent Number	>Estimated Expiration	>Supplementary Protection Certificate	>SPC Country	>SPC Expiration

Details for Patent: 9,259,425

Which drugs does patent 9,259,425 protect, and when does it expire?

Summary for Patent: 9,259,425